Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

158 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma.
Levenga H, Schaap N, Maas F, Esendam B, Fredrix H, Greupink-Draaisma A, de Witte T, Dolstra H, Raymakers R. Levenga H, et al. Among authors: raymakers r. Biol Blood Marrow Transplant. 2010 Mar;16(3):320-32. doi: 10.1016/j.bbmt.2009.10.006. Epub 2009 Oct 14. Biol Blood Marrow Transplant. 2010. PMID: 19835972 Free article. Clinical Trial.
Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients.
Hobo W, Strobbe L, Maas F, Fredrix H, Greupink-Draaisma A, Esendam B, de Witte T, Preijers F, Levenga H, van Rees B, Raymakers R, Schaap N, Dolstra H. Hobo W, et al. Among authors: raymakers r. Cancer Immunol Immunother. 2013 Aug;62(8):1381-92. doi: 10.1007/s00262-013-1438-2. Epub 2013 Jun 2. Cancer Immunol Immunother. 2013. PMID: 23728352 Free PMC article. Clinical Trial.
Multiple myeloma patients receiving pre-emptive donor lymphocyte infusion after partial T-cell-depleted allogeneic stem cell transplantation show a long progression-free survival.
Levenga H, Levison-Keating S, Schattenberg AV, Dolstra H, Schaap N, Raymakers RA. Levenga H, et al. Among authors: raymakers ra. Bone Marrow Transplant. 2007 Aug;40(4):355-9. doi: 10.1038/sj.bmt.1705742. Epub 2007 Jun 11. Bone Marrow Transplant. 2007. PMID: 17563732 Clinical Trial.
Dynamics in chimerism of T cells and dendritic cells in relapsed CML patients and the influence on the induction of alloreactivity following donor lymphocyte infusion.
Levenga H, Woestenenk R, Schattenberg AV, Maas F, Jansen JH, Raymakers R, De Mulder PH, van de Wiel-van Kemenade E, Schaap N, de Witte T, Dolstra H. Levenga H, et al. Among authors: raymakers r. Bone Marrow Transplant. 2007 Sep;40(6):585-92. doi: 10.1038/sj.bmt.1705777. Epub 2007 Jul 16. Bone Marrow Transplant. 2007. PMID: 17637687 Clinical Trial.
Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study.
Lokhorst HM, van der Holt B, Cornelissen JJ, Kersten MJ, van Oers M, Raymakers R, Minnema MC, Zweegman S, Janssen JJ, Zijlmans M, Bos G, Schaap N, Wittebol S, de Weerdt O, Ammerlaan R, Sonneveld P. Lokhorst HM, et al. Among authors: raymakers r. Blood. 2012 Jun 28;119(26):6219-25; quiz 6399. doi: 10.1182/blood-2011-11-393801. Epub 2012 Mar 22. Blood. 2012. PMID: 22442350 Free article. Clinical Trial.
Reduced relapse rate in upfront tandem autologous/reduced-intensity allogeneic transplantation in multiple myeloma only results in borderline non-significant prolongation of progression-free but not overall survival.
Lokhorst HM, van der Holt B, Cornelissen JJ, Kersten MJ, van Oers M, Raymakers R, Minnema MC, Zweegman S, Bos G, Schaap N, Wittebol S, de Weerdt O, Ammerlaan R, Sonneveld P. Lokhorst HM, et al. Among authors: raymakers r. Haematologica. 2015 Dec;100(12):e508-10. doi: 10.3324/haematol.2015.128728. Epub 2015 Sep 4. Haematologica. 2015. PMID: 26341740 Free PMC article. Clinical Trial. No abstract available.
158 results